Niagen Bioscience, Inc. NAGE

Independent preclinical study published in Nature Communications identifies CD38 as a key driver of NAD+ depletion in aging placental tissue. It shows NMN is degraded by CD38 while NR can inhibit CD38, restore NAD+ levels, and improve placental, fetal, and offspring outcomes in aged mice. In human placentas from older mothers, NAD+, NADH, and NADP+ were lower, and higher levels of these metabolites correlated with higher infant birth weight. The study also found CD38-expressing macrophages deplete NAD+ in neighboring cells, and NR administration or a CD38 inhibitor restored NAD+ and improved outcomes. NR used in the study was not Niagen; Niagen Bioscience did not conduct or fund the work. The findings support mechanistic reasons NR may outperform NMN in high-CD38 tissues, though clinical validation is needed. Preclinical results bolster NR-based NAD+ therapies and could influence investor sentiment toward Niagen NR products.

Niagen Bioscience, Inc. (NAGE) engages veteran pharmaceutical executives and biotechnology experts to advance its drug development program and drive strategic business growth. Engagement of experts strengthens drug development capabilities and supports long-term business expansion.

Niagen Bioscience expands Tru Niagen retail footprint through partnerships with GNC and Sam's Club. Retail partnerships with GNC and Sam's Club increase product distribution and revenue potential.

Niagen Bioscience expands NAD+ product availability via Walmart retail push, targeting broader healthy-aging market reach and brand repositioning. Walmart distribution expands Niagen product accessibility and visibility at scale.

Niagen Bioscience reports new aging study results that strengthen the case for a higher fair value on its shares. New aging study data plus explicit higher fair value thesis can materially shift investor sentiment and valuation multiples.

Niagen Bioscience launches Tru Niagen on Walmart.com to expand consumer access and diversify e-commerce channels. Walmart.com launch broadens retail distribution and supports incremental sales growth.

Niagen Bioscience Inc (NAGE) Q2 2026 earnings call highlights e-commerce surge and China progress. E-commerce surge and China expansion signal significant growth opportunities for Niagen Bioscience.

Niagen Bioscience, Inc. released its second quarter 2026 financial results. Quarterly financial results directly affect stock valuation and investor sentiment.

Niagen Bioscience selects Evotec to advance preclinical development for NB4168. Partnership advances preclinical work on NB4168 and may support future pipeline progress.

Niagen Bioscience announced a new analysis of prior clinical studies showing Niagen (NR) supplementation improved a muscle-specific marker of biological aging. Reinforcement of NR efficacy via retrospective analysis may modestly lift product credibility and near-term sentiment without altering core trajectory.

Niagen Bioscience received U.S. FDA Rare Pediatric Disease Designation and European Medicines Agency Orphan Medicinal Product Designation for NB4168 to treat Ataxia Telangiectasia. FDA Rare Pediatric Disease and EMA Orphan designations grant Niagen Bioscience regulatory incentives and market exclusivity that can accelerate development and boost commercial prospects for NB4168.

Niagen Bioscience launches pharmaceutical program for accelerated aging and rare genetic diseases. Pharmaceutical program launch targets high-potential markets in aging and rare diseases.

Niagen Bioscience Inc. renamed its research program to advance NAD+ applications. Renaming signals strategic focus on NAD+ applications that may affect innovation positioning.

Niagen Bioscience, Inc. (NAGE) valuation reassessed after strong earnings and launch of new NAD+ delivery initiatives. Strong earnings combined with new NAD+ delivery initiatives indicate major strategic advancements poised to significantly boost valuation and market performance.

Niagen Bioscience (NAGE) advances telehealth platform for NAD+ therapies, raising questions on whether it redefines the company's core therapeutic focus. Telehealth NAD+ initiative constitutes a major strategic expansion that could reshape NAGE's therapeutic priorities and market positioning.

Niagen Bioscience Inc. (NAGE) Q1 2026 earnings call summary covers quarterly financial results, operational updates, and forward-looking guidance. Q1 earnings call summary discloses key financial metrics and strategic outlook, likely driving significant shifts in investor sentiment and stock performance.

Niagen Bioscience, Inc. (NAGE) released Q1 2026 earnings call transcript detailing financial results, operational updates, and forward guidance. Q1 2026 earnings call transcript covers financial performance and strategic outlook with potential to drive significant market reaction and trajectory shifts.

Niagen Bioscience, Inc. (NAGE) reported Q1 earnings and revenues surpassing analyst estimates. Exceeding Q1 earnings and revenue estimates positively impacts financial performance and investor sentiment but remains limited to one quarter.

Niagen Bioscience, Inc. (NAGE) reported first quarter 2026 financial results. Quarterly financial results disclosure affects financial performance and market sentiment to a moderate degree.

Niagen Bioscience, Inc. (NAGE) launches Niagen Plus Telehealth Platform featuring an at-home injection kit offering. Launching a telehealth platform with at-home injection kits marks a major strategic expansion into accessible healthcare delivery.

Niagen Bioscience, Inc. (NAGE) added Olympia Pharmaceuticals to its 503B compounding partner network for Niagen Plus™, expanding access to the NAD+ boosting supplement through additional sterile compounding facilities. Adding Olympia Pharmaceuticals as a 503B compounding partner strengthens Niagen Bioscience's distribution and production network for Niagen Plus™, enabling greater market penetration and revenue potential.

Niagen Bioscience (NAGE) gains strong market positioning from a recent dietary supplement ingredient monograph, enhancing credibility and sales potential. Recent monograph provides regulatory validation that significantly boosts NAGE's competitive edge and investor appeal in supplements.

Niagen Bioscience, Inc. (NAGE) pivots its narrative with introduction of new Q4 financial models and injectable products, potentially reshaping investor outlook and operational strategy. New Q4 models and injectables signal major strategic advancements in biotech operations and market positioning.

Niagen Bioscience, Inc. (NAGE) collaborates with the United States Pharmacopeia (USP) to establish the first-ever USP monograph for Nicotinamide Riboside Chloride (NRCl), the patented form in Niagen®. First-ever USP monograph for NRCl validates Niagen Bioscience's patented ingredient, boosting credibility, regulatory standing, and market competitiveness.

Canaccord Genuity lowered its price target on Niagen Bioscience, Inc. (NAGE) following updated forecasts after Q4 results. Analyst price target cut post-Q4 reflects revised forecasts, likely affecting financial outlook and investor sentiment moderately.

Niagen Bioscience, Inc. (NAGE) announces its first partnership with OneSpaWorld to introduce Niagen IV therapy in cruise ship clinics, delivering NAD-boosting treatments to passengers at sea. Partnership expands Niagen IV access to cruise ship passengers through OneSpaWorld clinics, boosting distribution and revenue potential without fundamentally altering core operations.

Niagen Bioscience (NAGE) narrative shifts as analysts update price targets upward amid growing potential in injectables development. Shifts in price targets and injectables potential represent major strategic developments likely to alter NAGE's investor sentiment and trajectory.

Niagen Bioscience, Inc. (NAGE) has increased its share repurchase program to $20 million. Expanding the share repurchase to $20 million signals financial strength and supports stock price by reducing outstanding shares.

Niagen Bioscience, Inc. (NAGE) surpasses 300 external research agreements from leading global institutions on Niagen®, contributing to 45 published clinical studies. Milestone of 300 research agreements and 45 clinical studies significantly validates Niagen® and enhances NAGE's competitive positioning and investor sentiment.

Niagen Bioscience, Inc. (NAGE) launches Niagen® Skincare Innovation Lab and debuts dermatologist-tested Niagen NanoCloud™, a skincare innovation from Tru Niagen powered by patented Niagen®. Launching a dedicated skincare innovation lab and debuting a new patented, dermatologist-tested product marks a significant strategic expansion into the skincare market.